Insider trade

Reshma Rangwala, Officer at Karyopharm Therapeutics, sold ~$2.6K of Karyopharm Therapeutics shares.

~$2.6K
Approx. value · 419 sh @ $6.17
29K
Holds after · shares reported
Traded
Apr 23, 2025
Filed
Apr 24, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 4, 2025Insider · 6 peopleInsiders: 6 sales (~$161K)
  2. Apr 4, 2025InsiderCEO sold ~$916 of KPTI shares in the open market
  3. Apr 23, 2025 · this disclosureInsiderOfficer sold ~$2.6K of KPTI shares in the open market

What came next

  1. May 6, 2025InsiderCEO sold ~$1.7K of KPTI shares in the open market
  2. Jul 22, 2025InsiderOfficer sold ~$952 of KPTI shares in the open market
  3. Jul 29, 2025InsiderOfficer sold ~$835 of KPTI shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Karyopharm Therapeutics

For Karyopharm Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KPTI page.

Other recent filings by Reshma Rangwala, EVP & Chief Medical Officer

The full history of Reshma Rangwala, EVP & Chief Medical Officer is on the profile page.

How this filing works

Other disclosures at Karyopharm Therapeutics

Everything OQRO holds on this company is on its KPTI page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data